Intensive monitoring of duloxetine: results of a web-based intensive monitoring study by Linda Härmark et al.
PHARMACOEPIDEMIOLOGYAND PRESCRIPTION
Intensive monitoring of duloxetine: results of a web-based intensive
monitoring study
Linda Härmark & Eugène van Puijenbroek &
Kees van Grootheest
Received: 21 February 2012 /Accepted: 12 May 2012 /Published online: 12 June 2012
Abstract
Purpose Duloxetine (Cymbalta®) is a serotonin (5-HT) and
norepinephrine (NE) re-uptake inhibitor indicated for the
treatment of depression, diabetic peripheral neuropathic
pain and general anxiety disorder. The aim of this study is
to gain insight in the user and safety profile of duloxetine in
daily practice, reported by patients via a web-based inten-
sive monitoring system during their first 6 months of use.
Methods First-time users of duloxetine were identified
through the first dispensing signal in the pharmacy. Patient
demographics and information about drug use and adverse
drug reactions, ADRs, were collected through electronic
questionnaires sent 2 and 6 weeks, 3 and 6 months after
the start of duloxetine administration. ADRs were quantified
and signal detection was performed on a case by case basis.
Results Three hundred and ninety-eight patients registered
for the study; 69.1 % were female. Depression was the main
indication. Three hundred and three patients (76.1 %) filled
in at least one questionnaire and 78.9 % of these reported an
ADR. Serious ADRs were reported by 4 patients. Three new
signals were identified, amenorrhea, shock-like paraesthe-
sias and micturition problems.
Conclusions Web-based intensive monitoring is an obser-
vational prospective cohort study mirroring the use and
ADRs of duloxetine in daily practice. This study indicates
that duloxetine is a relatively safe drug as used by patients
for six months in daily practice, but the aforementioned
signals need to be evaluated in more detail.
Keywords Post-marketing surveillance . Intensive
monitoring . Web . Duloxetine . Adverse drug reactions
Introduction
Duloxetine (Cymbalta®) is registered in the European Union
for the treatment of major depressive disorder, diabetic
peripheral neuropathic pain and generalised anxiety disorder
[1]. It is a serotonin (5-HT) and norepinephrine (NE) re-uptake
inhibitor with almost equal affinity for binding to NE and 5-HT
transport sites, with little affinity for other receptors such as
muscarinic, histaminergic, alpha-adrenergic, dopaminergic,
serotonergic and opioid receptors, suggesting that it might
have a more benign adverse drug reaction profile compared
with other antidepressive drugs [2].
The efficacy and safety of duloxetine for the treatment of
the registered indications were investigated in clinical trials
[1, 3–6]. Clinical trials are primarily designed to prove
efficacy. For detection of adverse drug reactions (ADRs),
clinical trials have a number of limitations, including a
homogeneous population that does not mirror the target
population concerning age, gender, comorbidity and come-
dication, limited sample size and a limited duration [7].
Because of these limitations it is essential to monitor the
safety of duloxetine in clinical practice in order to get a clear
picture of its ADR profile.
Spontaneous reporting has been the backbone of pharma-
covigilance ever since the thalidomide disaster 50 years ago.
In a spontaneous reporting system health care professionals
and increasingly also patients can submit reports of ADRs.
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These reports can lead to the detection of a new signal. A
signal is defined by the WHO as “Reported information on a
possible causal relationship between an adverse event and a
drug, the relationship being unknown or incompletely docu-
mented” [8].
Spontaneous reporting is a passive form of drug surveil-
lance, where one is dependent on the willingness of health
care professionals and patients to report. In order to gain
more information about a certain drug, a more active form of
drug surveillance is necessary [9, 10].
In 2006, the Netherlands Pharmacovigilance Centre
Lareb, which is responsible for the collection and analysis
of spontaneous reports in the Netherlands, introduced a
web-based intensive monitoring system called Lareb Inten-
sive Monitoring (LIM). LIM is a non-interventional pro-
spective observational cohort that follows users of certain
drugs during a certain period of time. In LIM, patients
eligible for inclusion are identified in community pharma-
cies through a first dispensing signal. The patient receives
information about the study and if willing to participate, the
patient registers online. After registration, questionnaires are
sent by e-mail at specific points in time. In these question-
naires questions are asked about patient characteristics, drug
use and possible ADRs. The LIM methodology has been
described in more detail elsewhere [11, 12]. The aim of this
study is to gain insight into the user and safety profile of
duloxetine in daily practice, reported by patients via a web-




The population consisted of first-time users of duloxetine,
identified through the first dispensing signal in intensive mon-
itoring participating pharmacies between 1 November 2006
and 30 April 2008. Data were collected between 1 November
2006 and 31 October 2008.
Data collection
When registering for the study, patients were asked to pro-
vide an e-mail address, which was used for all further
correspondence. During registration, patient characteristics
and information about duloxetine use and concomitant drug
use were collected. After registration, the patient received
questionnaires by e-mail 2 and 6 weeks, and 3 and 6 months
after starting the drug, where information about possible
ADRs due to duloxetine use was collected. If the patient
did not fill in the questionnaire immediately, a reminder was
sent 5 days later. If a questionnaire was not completed
4 weeks after the reminder, the patient was considered “lost
to follow-up” for that questionnaire. If the patient stopped
the use of duloxetine, or in the event of death of the patient
or if the patient actively chose to stop his participation in the
study, the patient did not receive any more questionnaires.
The participation in the study was then considered to be
completed.
The indication and ADRs were coded using the
Medical Dictionary for Regulatory activities (MedDRA)
on a Lower Level Term (LLT) level by a qualified
assessor [13]. Study drug and co-medication were coded
using the Dutch Drug dictionary, Z-index [14]. If a
report was judged to be serious according to the Coun-
cil for International Organisations of Medical Sciences
(CIOMS) criteria, which includes (prolongation of) hos-
pitalisation, life-threatening events, events leading to
death, disabling events, congenital abnomalities, and
other medically significant events [15], and was also
assessed as being serious by the assessor, a copy of
the report was exported to the national database con-
taining all spontaneous reports, where it was handled
according to the regulations regarding serious adverse
drug reaction reports. The workflow of Lareb Intensive
Monitoring has been described in more depth elsewhere
[12].
Analysis
The frequencies were calculated for gender, age, drug
strength used, daily dose and past use of drugs for
depression and neuropathic pain. The number of patients
reporting a possible ADR, the percentage of serious
ADRs, and the incidence of different ADRs were cal-
culated. Even though a patient could report the same
adverse drug reactions in all four questionnaires, one
specific reaction was only counted once for each indi-
vidual when calculating incidences. The possible ADRs
were divided into labeled or not labeled according to
the European Public Assessment Report (EPAR) [1].
Reactions that were not labeled and reactions that were
labeled but for other reasons were considered to be of
potential interest (selection made by one pharmacist
[LH] and one physician [EP]) were analyed on a case
by case basis. Labeled reactions were considered to be
of interest if frequency differences were found between
the cohort and the EPAR.
A comparison between the patients who only filled in the
registration form and the patients who provided data on
whether or not they had experienced any possible ADRs
was made on the basis of age, gender and daily dosage.
Significance was declared at the p<0.05 α level. Data were
retrieved using Microsoft Access. Statistical analysis was
performed using SPSS version 17.
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Results
Between 1 November 2006 and 30 April 2008, 398 patients
registered for the duloxetine study; 69.1 % of these were
female. The average age was 47.0 (SD 12.3 ) years, ranging
from 14 to 82 years. 66.7 % of the patients used duloxetine
for depression, 16.1 % for neuropathic pain and 4.3 % for
fibromyalgia.
As much as 81.4 % of the population cohort used dulox-
etine capsule 30 mg and 16.6 % were on 60 mg. In 3.0 % of
the cases the capsule strength used was not specified. The
average daily dosage was 49.1 mg. Two hundred and thirty-
nine patients answered the question asking if they had used
any drugs previously for the treatment of depression and/or
neuropathic pain. Of the patients who answered the ques-
tion, 97 (40.6 %) patients had used other drugs for the same
indication in the past. The most commonly used drugs were
SSRIs, including venlafaxine (55 patients), tri-cyclic anti-
depressants (13), other anti-depressants (12), and benzodia-
zepines (10).
Of the 398 patients who registered for the study, 303
patients (76.1 %) filled in at least one questionnaire. Since
patients were allowed to skip questionnaires, the number of
the respondents to the first questionnaire is lower than the
total number of respondents. For an overview of the re-
sponse rate see Fig. 1. There were no statistically significant
differences found regarding sex, age, and daily dosage be-
tween patients filling in a questionnaire compared with the
patients who only registered for the study.
Two hundred and thirty-nine of the patients who filled in
at least the first questionnaire reported an adverse drug
reaction (78.9 %). In total, 152 different adverse drug reac-
tions were reported. The reported adverse drug reactions, in
absolute number as well as percentages, are presented in
Table 1. Serious adverse drug reactions were reported by 4
patients (1.3 %). One was categorised as life- threatening, 2
required hospitalisation and 1 patient died. For an overview
of these reactions see Table 2.
Of the 71 ADRs that were reported two or more times
with the LIM system, 52 are explicitly mentioned in the
EPAR for duloxetine.
Signals
Events not labeled in the EPAR and events already labeled
and for other reasons considered to be of interest (e.g.,
incidence differences) were analysed on a case by case
basis.
Amenorrhoea
In the LIM cohort 2 cases of amenorrhea were reported. The
first report concerns a woman aged 49 who experienced
amenorrhea 20 days after the start of duloxetine for the
treatment of neuropathic pain. The menstruation returned
after withdrawal of duloxetine. Concomitant medication
was several inhalation drugs (salbutamol/iptratropium,
budesonide, formoterol), montelukast, esomeprazole, oxy-
codone and calcium carbonate/colecalciferol. The second
report concerns a woman aged 45 who experienced amen-
orrhea just after the start of duloxetine for the treatment of
depression. After missing two periods, the menstruation
returned without change in duloxetine dose. No concomitant
medication was reported.
Shock-like paraesthesia
In the EPAR the general term paraesthesia is mentioned as
an ADR. In the LIM cohort two reports of electric shock
sensation, a special form of paraesthesia, were received. The
first report concerns a man aged 35 who experienced “small
electric shocks” in the head 3 days after starting duloxetine











Fig. 1 Response rate of the questionnaires
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eventually stopping the drug, the patient recovered. Con-
comitant medication consisted of lormetazepam and losar-
tan/hydrochlorothiazide. The second report concerns a
female aged 36 who experienced “a voltage in the brain”
on the day of starting duloxetine treatment for depression.
The patient recovered upon discontinuation of duloxetine.
Comcomitant medication comprised oxazepam and ethiny-
lestradiol/gestoden.
Micturition problems
The EPAR of duloxetine mentions urinary disorders as
uncommon (frequency 0.1–1 %), except dysuria (frequency
1–10 %). In the LIM cohort urinary disorders were reported
more frequently; a total of 17 patients (5.6 %) reported
urinary disorders. Ten patients reported urinary hesitation,
sometimes in combination with a decreased urine flow.
Seven patients reported an increase in the micturition fre-
quency. Of the 17 patients with urinary disorders, 11 were
men and 6 were women. In 5 cases a positive dechallenge
was reported; in another 5 cases the problems seem to
disappear while continuing duloxetine treatment. In 4 cases
the drug was continued and the patient did not recover. In 2
cases the duloxetine was withdrawn, but the patient had not
(yet) recovered. In 1 case the outcome was not reported.
Discussion
Web-based intensive monitoring gives an overview of the
safety profile of duloxetine in daily practice as well as
capturing the characteristics of its users.
User characteristics
In the study the majority (69.1 %) of participants were
female, which is consistent with the fact that both depres-
sion and neuropathic pain are more prevalent in women [16,
17]. The ages ranged from 14 to 82 years with 2 patients
below 18 years of age. Duloxetine is registered for use in
adults [1] and this shows that duloxetine, although it is a
relatively new drug, is prescribed to younger patients off
label. The majority of patients started with the 30-mg cap-
sule and the average daily dosage was 49.1 mg, which is low
compared with the recommended starting dosage of 60 mg
once daily for the treatment of depression and diabetic
peripheral neuropathic pain [1]. In this study duloxetine is
used mostly as a treatment for depression; only 16.1 % of
the patients used duloxetine for neuropathic pain. This is
quite surprising since there were many treatment options for
depression on the market at the time of the introduction of
duloxetine, but few drugs registered for the treatment of
neuropathic pain. However, many of the patients who re-
ceived duloxetine stated that they had used other drugs for
the same indication in the past, and SSRIs, together with
TCAs and other antidepressant drugs were the most fre-
quently mentioned, indicating that the patients who receive
duloxetine did not respond to treatment with other antide-
pressant drugs. Another possibility is that the prevalence of
depression is higher than the prevalence of neuropathic pain.
It is surprising that almost 5 % stated that they used dulox-
etine for the treatment of fibromyalgia, even though this is
not a registered indication in the European Union; however,
in the USA duloxetine is indicated for the treatment of
fibromyalgia [18]. Just as the intensive monitoring study
of pregabalin, which is another drug indicated for the treat-
ment of neuropathic pain, showed [12], it seems that
Table 1 The reported adverse drug reactions, in absolute numbers as














Sleep disorder 24 7.9
Decreased appetite 19 6.3
Diarrhoea 15 5.0
Decreased libido 13 4.3




Weight increase 8 2.6
Restlessness 7 2.3
Erectile dysfunction 7 2.3
Myalgia 7 2.3
Vision blurred 7 2.3
Upper abdominal pain 7 2.3
Paraesthesia 6 2.0
Restless legs syndrome 6 2.0
Abnormal dreams 6 2.0
Tremor 6 2.0
Pollakiuria 5 1.7
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duloxetine is prescribed to patients with fibromyalgia off
label in the Netherlands.
Adverse drug reactions
The ADRs most frequently reported in this study correspond
to the most frequently reported ADRs in pre-registration
trials, as well as in other trials [2–6, 19, 20]. The frequencies
obtained with the LIM system are similar to those stated in
the EPAR, except for a few cases. Of the possible ADRs
reported via the web-based intensive monitoring system,
three are worth additional attention.
Two reports of amenorrhea were reported. Even though
the age of the patients (49 and 45 years old respectively)
suggest that the amenorrhea could be due to the women
entering the menopause, the absence of other symptoms
relating to the menopause as well as the positive dechallenge
in one case supports a causal relationship. Amenorrhea is
not listed in the EPAR of duloxetine (the unspecified men-
opausal symptoms are), but can be explained from a mech-
anistic point of view as it is a clinical manifestation of
hyperprolactinaemia that is mentioned in the EPAR and is
caused by raised levels of serotonin, which is a modulator of
prolactin secretion [21].
Shock-like paraesthesia consists of sensory perceptions
of short electric low-voltage discharges, usually localised in
the brain. In addition to these two reports, the Netherlands
Pharmacovigilance Centre received three reports of shock-
like paraesthesia through their spontaneous reporting
system, strengthening this signal [22]. Shock-like paraesthe-
sia has been described with the use of SSRIs [23, 24]. The
symptoms usually occur during drug withdrawal, but have
also been described with ongoing therapy. As it might not
always be recognised as an ADR by patients and health care
professionals, it is worth paying extra attention to it.
The EPAR for duloxetine mentions urinary disorders
except dysuria as being uncommon (frequency 0.1–1 %).
In the LIM cohort urinary disorders were reported more
frequently; a total of 17 patients reported urinary disorders,
mainly urinary hesitation and increased micturition frequen-
cy. It is notable that 11 of the 17 patients (64.7 %) with
urinary problems were men, since only 30 % of the cohort
are men. Only one of the men reported the use of drugs for
treatment of benign prostate hypertrophy, which might be a
confounding factor for the urinary disorders. The low fre-
quency in the EPAR is surprising, especially for urinary
hesitation, since duloxetine is registered under another
brand name (Yentreve®), which is indicated for stress uri-
nary incontinence [25].
Strengths and weaknesses
Web-based intensive monitoring is an observational pro-
spective cohort study mirroring the use and ADRs of dulox-
etine in daily practice compared with clinical studies, which
have strict inclusion and exclusion criteria.
Eligible patients were identified in community pharma-
cies; however, not all patients eligible for inclusion


















27 days for the suicide attempt,
a few days for the dry mouth
and constipation, the drug was
withdrawn, patient is recovering
Patient used duloxetine for
depression, treatment with








26 days for the loss of appetite,
4 days for the constipation, a few
hours for the headache, the
drug was withdrawn, the patient
has recovered from the loss of
appetite, but has not recovered
from the two other events
Patient used duloxetine for
depression, hospitalisation
was because of drug use;
however, it is not clear what












Oxazepam All reactions occurred in the first
month, the drug dose was not
changed. The outcome of the
suicidal ideation and the
restlessness is unknown, the
patient has recovered from all
other events.









None reported One month, patient died Patient used duloxetine for
depression. The death was
reported by the patient's
partner
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participated in the study. Data on duloxetine dispensing
during the inclusion period were provided by the Dutch
Foundation for Pharmaceutical Statistics [26] and the LIM
response rate was 3.5 % of all patients receiving a first
prescription of duloxetine during the inclusion period. This
might contribute to non-response bias. There is no informa-
tion about the patients who did not participate; it is therefore
not possible to know if the patients eventually participating
in the study are representative of all patients using dulox-
etine. Non-response bias in a LIM study has been investi-
gated and it showed that patients participating in LIM are in
general younger and use a little less co-medication (0.8)
than non-responders (Härmark et al., submitted for publica-
tion). However it cannot be assumed that younger patients
experience fewer ADRs than older patients [27, 28].
In this study it was chosen to use the patient as a source
of information. This has the advantage that adverse drug
reactions are reported by the person who has actually expe-
rienced the reaction. Since patients do not have any “pro-
fessional filter” in what they report, compared with health
professionals, it enhances the chance of finding new ADRs
that would not be considered ADRs, and therefore not
reported by health professionals. For example, shock-like
paraesthesias is an ADR that is primarily reported by
patients compared with health professionals at the Nether-
lands Pharmacovigilance Centre Lareb. Since the patient is
the source of information, it might be difficult to obtain
information about fatal outcomes. In this study we received
one report with a fatal outcome, and this was reported by the
patient’s wife, showing that patient-based tools can also
collect information about fatal outcomes.
It is surprising that almost 80 % of the patients who filled
in a questionnaire reported an ADR. This is a rather high
percentage and it is possible that patients who experienced
an ADR were more inclined to fill in a questionnaire than
those who did not experience ADRs, but analyses showed
no difference in gender, age, and daily duloxetine dosage
between the groups. Another reason for the high percentage
might be channeling. Forty percent of the participants had in
the past used one or more drugs for the same indication. It is
not known if they switched because of a lack of efficacy or
because of ADRs. If the latter were the reason for switching,
it can be assumed that these patients might have an in-
creased susceptibility to ADRs compared with others.
Conclusion
This study indicates that the ADR profile of duloxetine as
reported by patients over 6 months in daily practice is
similar to the profile described in the EPAR of duloxetine
[1]. Four patients (1.3 %) experienced a serious adverse
drug reaction, of which one was fatal because of electrolyte
disturbances. In addition, three signals of a possible new
adverse drug reaction were identified; namely, amenorrhoea,
shock-like paraesthesias, and urinary disorders and these
need to be further evaluated in more detail. Web-based
intensive monitoring has been shown to be a useful and
efficient method of gaining insight into the behavior of
new drugs in daily practice.
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